Vanguard Personalized Indexing Management LLC Acquires 3,876 Shares of IQVIA Holdings Inc. $IQV

Vanguard Personalized Indexing Management LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 14.4% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 30,837 shares of the medical research company’s stock after buying an additional 3,876 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in IQVIA were worth $5,857,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Versant Capital Management Inc increased its stake in IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after buying an additional 53 shares during the period. Private Trust Co. NA boosted its holdings in shares of IQVIA by 12.5% in the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after purchasing an additional 67 shares during the period. CVA Family Office LLC grew its stake in IQVIA by 11.6% in the third quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock worth $124,000 after purchasing an additional 68 shares in the last quarter. E Fund Management Co. Ltd. lifted its holdings in shares of IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock worth $331,000 after buying an additional 74 shares during the period. Finally, Harbor Capital Advisors Inc. grew its position in shares of IQVIA by 2.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 2,795 shares of the medical research company’s stock worth $531,000 after buying an additional 78 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQVIA stock traded down $1.60 during midday trading on Wednesday, hitting $239.44. The company had a trading volume of 70,601 shares, compared to its average volume of 1,140,202. The company has a fifty day simple moving average of $230.03 and a 200 day simple moving average of $207.28. The stock has a market cap of $40.78 billion, a price-to-earnings ratio of 32.95, a PEG ratio of 2.44 and a beta of 1.36. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.84 earnings per share. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IQV. Barclays set a $230.00 price objective on shares of IQVIA in a research note on Monday, December 15th. Mizuho set a $266.00 price objective on shares of IQVIA in a research note on Friday, January 9th. Evercore ISI boosted their price objective on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. TD Cowen increased their target price on IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus upped their price objective on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $251.06.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.